ME-PCR combined
with cASO resulted in a threefold higher detection rate than has previously been reported and suggests that other studies may have underestimated the frequency of K-ras mutations. [2] [3] [4] [5] , with the most common mutation being Gly-i2 to Val-12 [I] .
A number of techniques have previously been used to identify these mutations.
These include dot-blot hybridization of radiolabeled oligonucleotides to PCR-amplified ras DNA [6] , primermediated restriction endonuclease digestion [7] , and RNase cleavage [8] . The sensitivity of these methods is 1-10%; i.e., they can detect cells possessing a mutation among cells with the wild-type allele if they are present in at least 1-10% of the total cell population.
However, solid tumor specimens usually contain significant numbers of nonneoplastic stromal and inflammatory cells and the mutant sequence may not reach this level. In PCR-based methods this heterogeneity increases the number of amplified nonmutated sequences and ultimately decreases the sensitivity of detection. Previous techniques may therefore have been prone to false negatives and the number of tumor mutations underestimated.
Improved methods have shown a considerable increase in sensitivity over previous assays. Mutant-enriched PCR amplification (ME-PCR), a modification of the primer-mediated restriction digestion method [9] , has been reported to be highly sensitive for the detection of K-ras mutations in pancreatic carcinoma
[JO] and colonic effluents from colorectal cancer patients [I I]. The amplification refractory mutation system (ARMS) works by selective amplification of mutated alleles, involving 3' mismatched primers and optimized PCR conditions [12] . This technique has been found to be suitable for detecting ras mutations in both pancreatic juice and peripheral blood of pancreatic adenocarcinoma patients [13] and in sputum from lung cancer patients [14] .
In this study we have compared the sensitivity of competitive allele-specific oligonucleotide (cASO) hybridization with that of the ME-PCR and ARMS techniques in detecting the Val-i2 ' Nonstandard abbreviations: ME-PCR, mutant-enriched polymerase chain reaction; ARMS, amplification refractory mutation system; cASO, competitive allele-specific oligonucleotide; and PBL, peripheral blood lymphocytes. 
ME-PCR.
Reactions involving the protocol outlined in Fig. 1 were performed essentially as previously described /10/. DNA was amplified for 15 cycles in the first PCR reaction with 50 pmol of primers P5 and P6 at an annealing temperature of 55 #{176}C ( were digested as before with BstNI, and the whole digest mix was electrophoresed through an agarose gel. Fig. 3 shows that the sensitivity obtained by the use of the second PCR appears to DNA sequencing. Four samples, analyzed by ME-PCR, were selected at random and the genotypes were confirmed by direct sequencing of the amplified products.
Results

cASO hybridization.
Genomic DNA from the SW480 colon carcinoma cell line, which is homozygous for the K-ras codon Val-12 mutation [17] , was diluted with genomic DNA prepared from peripheral blood lymphocytes (PBL), which are homozygous wild-type at the same position in ratios from 1:1 to i:10. These mixtures were amplified by PCR with primers P1 and P2 and analyzed by using cASO hybridization.
The mutant signal could be detected at a 102 dilution in the PBL DNA as previously reported for p53 alleles [15] . Using this assay, we screened 74 colorectal carcinomas for the Val-12 mutation, detecting Val-12 mutations in 6 (8%) specimens ( Table 2 ). The frequency is similar to that observed by other investigators using assays of similar sensitivities [2, 18] .
ARMS.
The ARMS technique is capable of detecting a point mutation by using a PCR primer that is complementary to the mutated sequence and not the wild type. In this assay, primer P3 (Table 1) , which is complementary to the K-ras Val-12 muta- 
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tion, generates a mismatch with wild-type sequence and the amplification process fails. This assay can detect 1 mutant in 1000 (unpublished observations); this figure is somewhat lower than the sensitivity of 1: iO previously reported [13] . Although we used the same oligonucleotide sequences as ARMS primers, the discrepancy in sensitivity may be explained by differences in PCR conditions.
In our laboratory we found that successful amplification with the ARMS primers was achieved only when the annealing temperature was reduced 11 #{176}C below that reported [13] .
Larger nonspecific bands could be observed in those samples with an absence or a low contribution of mutant template.
However, this did not appear to affect the working of the ARMS assay. Subsequent analysis of colorectal tumor specimens (representative results in Fig. 2 ) revealed that Val-12 mutations were present in 12 of 74(16%) samples; 6 of these had been identified by cASO hybridization together with an additional 6 not ME(/ identified previously (see Table 2 ). be 1 mutant allele in i0 normal as detected by the presence of the 135-bp band on ethidium bromide-stained gels. This detection rate is similar to that previously reported [9] . However, a faint band in this position can also be seen for the PBL DNA alone-most likely due to incomplete digestion of the wild-type DNA by the BstNT enzyme even after a 16-h digestion period.
For a more specific diagnostic step to exclude false positives due to incomplete digestion, we screened the secondary ME-PCR products by using the cASO hybridization method instead of performing a second BstNI digest. cASO hybridization per allows the detection of 1% mutant sequence in a background of wild-type, but this method combined with ME-PCR carries a high degree of specificity to define the precise mutation at codon 12. Results in Fig. 4 show that the Val-12 mutation could be detected at 1:5000-1:10 000 (mutant:wild-type ratio (Table 2) . Representative results are shown in Fig. 5 . The same analysis of normal colonic mucosa specimens from 12 patients who had Val-12 tumor mutations showed the absence of the same mutation in this tissue (data not shown).
ME-PCR combined with cASO hybridization detected eight more tumors with Vat-i 2 mutations in addition to those already identified with ARMS, amounting to 27% of tumors. This value is 17-20% higher than results of previous studies [2, 18] and confirms the notion that the relatively insensitive methods used mutations.There did not appear to be any correlation between tumor stage and low frequency of the mutation (see Table 2 ).
Discussion
We have compared the sensitivities of cASO hybridization, ARMS, and ME-PCR for their ability to detect a low number of mutated K-ras alleles in the wild-type background. Although the ARMS method was 10 times more sensitive than cASO hybridization, the potential for false positives from samples that gave very faint bands upon gel analysis was higher in ARMS (in our PBL SW480
analysis only those that gave strong bands were recorded as positive). Despite the use of adequate controls with the ARMS assay, tube-to-tube variation can result in mispriming to wildtype template if slight differences in PCR conditions are encountered, and this has previously been reported to be a limiting factor in the use of ARMS [12] . In addition, there is also the potential for false negatives due to failed reactions. However, the latter problem may be overcome by including an unrelated internal amplification control with each reaction.
Previously, diagnosis of mutant and wild-type samples with ME-PCR has been made by BstNT digestion of the secondary PCR products and analysis by agarose gel electrophoresis [9] [10] [11] . Using this method, we found that wild-type PCR products generated from PBL DNA alone failed to digest completely, even after a 16-h incubation period. Thus a problem with this analysis as a diagnostic step is the generation of false positives. To overcome this, we used cASO hybridization to screen the secondary PCR products for the K-ras Val-12 mutation. The additional advantage of this step is that it allows us to define the exact codon 12 mutation involved. By using this combined method, the sensitivity of the assay was found to be 1 mutant allele in 5000 wild-type. This result is similar to that obtained by other investigators using ME-PCR [9, 10] , but the modification to the method allows absolute specificity in defining the mutation. ME-PCR, combined with conventional ASO hybridization, has been used for detecting K-ras mutation in adenocarcinoma of the pancreas [19] and an increase in mutation detection was similarly observed.
Analysis of normal bowel mucosa from 12 patients with Val-12 tumor mutations failed to detect the same mutation in normal tissue. In contrast, recent studies suggest that multiple K-ras mutations may occur in nonneoplastic mucosa in 18-25% of colorectal cancer patients [20] . However, these investigators reported the need to screen multiple samples from each patient, since mutations appeared to be localized in different areas of the large bowel. In our studies, only one normal mucosa specimen from each patient was available for analysis. Clearly this area needs to be investigated further.
The availability of sensitive assays makes it feasible to explore other aspects of oncogenesis such as the clonality of tumors. The clonal theory predicts that every neoplastic cell within a single tumor will possess the same mutation [21, 22] . The use of highly sensitive methods enables a mutation to be detected in cells that contribute only a minor fraction of the tumor. In support of this, there is now increasing evidence to suggest that tumors may contain multiple and genetically distinct clones [10, 23] . To date it has been reported that 40-50% of colorectal tumors possess a K-ras mutation [1] . However, if the sensitive ME-PCRJcASO hybridization assay is modified and used to screen for all codon 12 and 13 mutations, this figure could be a lot higher. This is in agreement with recent reports of the detection of K-ras mutations by sensitive methods in a variety of other malignancies [24, 25] . These findings may have important implications for the development of molecular screening assays to aid in the early diagnosis of cancer.
